Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Entresto Drug Analysis Report 2017-2026 - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: Entresto" drug pipelines has been added to ResearchAndMarkets.com's offering.

Entresto is a first-in-class angiotensin receptor/neprilysin inhibitor consisting of valsartan and sacubitril. Valsartan is an angiotensin receptor blocker (ARB) that competes with angiotensin II for binding to the AT1 receptor, while sacubitril is a prodrug that inhibits neprilysin, an enzyme responsible for the breakdown of several vasoactive peptides. The combined action of both molecules attenuates vasoconstriction and sodium retention, helping to improve the underlying pathology of chronic heart failure.

List of Figures

Figure 1: Entresto for chronic heart failure - SWOT analysis

Figure 2: Drug assessment summary of Entresto for chronic heart failure

Figure 3: Drug assessment summary of Entresto for chronic heart failure

Figure 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Entresto drug profile

Table 2: Entresto Phase III data in chronic heart failure

Table 3: Ongoing pivotal trials for Entresto in chronic heart failure

Table 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/76kwb3/entresto_drug?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215006093/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.